Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin for circadian sleep-wake disturbances in ocular disease
2017-002189-39Phase 3Unknown
- Sponsor
- University of Oxford
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of melatonin in circadian rhythm sleep disorder (CRSD), sponsored by University of Oxford. Status: unknown.
02
Drugs
melatonin
03
Conditions
circadian rhythm sleep disorder (CRSD)
Beyond the preview
Go deeper on 2017-002189-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002189-39.